Repare Therapeutics Inc · Q2 2023 earnings

Briefing

Reported financial results and provided a business update.

Repare Therapeutics reported progress in advancing clinical programs and presenting novel findings from clinical trials during the second quarter of 2023. The company is advancing camonsertib and lunresertib clinical programs and designated a new Polθ inhibitor RP-3467 for IND-enabling studies. Revenue from collaboration agreements increased, and cash reserves are expected to fund operations into 2026.

• Presented initial camonsertib-PARPi combination Phase 1/2 clinical data at AACR 2023 demonstrating durable clinical benefit across tumor types.
• Reported clinical proof of concept for lunresertib (RP-6306) in June 2023, including achievement of monotherapy safety and tolerability primary endpoints.
• Granted FDA Fast Track designation for lunresertib in combination with camonsertib for the treatment of adult patients with CCNE1 amplified, or FBXW7 or PPP2R1A mutated endometrial cancer in August.
• Initiated IND-enabling studies for newly designated Polθ inhibitor RP-3467.

Headline financials

Revenue & EPS history

Repare Therapeutics expects to report initial combination data of lunresertib with camonsertib in the fourth quarter of this year and host an R&D day focused on its ongoing pre-clinical programs and its overall pipeline in the fourth quarter of this year.